The success of copyright’s blockbuster initially sparked a boom for pharma, but recent shifts present a complicated outlook for shareholders. Lower-cost alternatives are eroding profits, and ongoing legal battles add further difficulty to the landscape. While specific companies could still see gains from related services, the general trajectory s